Needham raised the firm’s price target on Taysha Gene Therapies to $7 from $5 and keeps a Buy rating on the shares after its better than expected Q4 results. The company’s first two dosed adult patients have also maintained clinical benefits up to 35 weeks post-treatment while tapering steroid use, which answers a key Bear question regarding the initial activity of TSHA-102 in adults, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
- Options Volatility and Implied Earnings Moves Today, March 19, 2024
- Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024
- Is TSHA a Buy, Before Earnings?
- Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
